Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 67 (10), 1383-92

Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus

Affiliations
Review

Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus

Bart Staels et al. Drugs.

Abstract

Bile acids promote bile formation and facilitate dietary lipid absorption. Animal and human studies showing disturbed bile acid metabolism in diabetes mellitus suggest a link between bile acids and glucose control. Bile acids are activating ligands of the farnesoid X receptor (FXR), a nuclear receptor with an established role in bile acid and lipid metabolism. Evidence suggests a role for FXR also in maintenance of glucose homeostasis. Animal and human studies employing bile acid sequestrants (bile acid binding agents), which interrupt the enterohepatic circulation of bile acids and effectively reduce plasma cholesterol, support a link between bile acid and glucose metabolism. In lipid-lowering trials, bile acid sequestrants, such as colesevelam hydrochloride, colestyramine (cholestyramine) and colestilan (colestimide), have also been shown to lower plasma glucose and glycosylated haemoglobin levels, suggesting the utility of these agents as a potential therapy for type 2 diabetes. In this article, we review the relationship between bile acid metabolism and glucose homeostasis, and present data demonstrating the utility of bile acid sequestrants in the management of diabetes.

Similar articles

See all similar articles

Cited by 47 PubMed Central articles

See all "Cited by" articles

References

    1. J Biol Chem. 2003 Oct 3;278(40):39124-32 - PubMed
    1. Endocrinology. 2005 Mar;146(3):981-3 - PubMed
    1. J Lipid Res. 2006 Jan;47(1):215-27 - PubMed
    1. Gastroenterology. 1982 Oct;83(4):851-9 - PubMed
    1. J Lab Clin Med. 1990 Apr;115(4):441-8 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback